VOLUNTARY ANNOUNCEMENT - ACQUISITION OF F-STAR THERAPEUTICS, INC.

ADJUSTMENT TO CONVERSION PRICE OF EURO750,000,000 ZERO COUPON CONVERTIBLE BONDS DUE 2025

VOLUNTARY ANNOUNCEMENT CATEGORY 1 INNOVATIVE DRUG “TQC2938” INJECTION APPROVED FOR CLINICAL TRIAL

NEXT DAY DISCLOSURE RETURN

POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 6 JUNE 2022

AMENDED AND RESTATED ARTICLES OF ASSOCIATION

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MAY 2022

2021 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT